Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Stephen J. Ryan, MD, MA, is a Professor, Neuromuscular Medicine Program, Department of Neurology, University of Kentucky Medical Center, Lexington, KY. Funding source: This activity is supported ...

A recent comprehensive analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline reveals a promising future for individuals affected by this severe neurological disorder.

In addition, patients with myasthenia gravis, the Lambert-Eaton myasthenic syndrome, Guillain-Barre syndrome, chronic demyelinating polyneuropathy, sarcoidosis, neuro-Behcet's disease, paraneoplastic ...

Participants who respond to batoclimab therapy in Period 1 (responders are defined as those achieving a ≥1 point improvement from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and ...

HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) is a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP ...

Chronic inflammatory demyelinating polyneuropathy (CIDP ... diagnostic and treatment criteria from the European Academy of ...

Chronic inflammatory demyelinating polyneuropathy (CIDP ... for CIDP diagnosis and treatment from the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) strongly recommends initial ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...